A. J. Van Wijnen

TL;DR: This review focuses on components of transcriptional regulation that function in growth control during osteoblast proliferation and those that postproliferatively contribute to maturation of the bone phenotype.

TL;DR: Northern blot analysis and competitive RT-PCR demonstrated that Dlx-5 and the bone-specific osteocalcin genes exhibit similar up-regulated expression during the mineralization period of osteoblast differentiation.

TL;DR: Mechanisms of Runx2 function were identified in co-culture studies showing that PC3 cells promote osteoclastogenesis and inhibit osteoblast activity, and indicate that Runx 2 is a key regulator of events associated with prostate cancer metastatic bone disease.

TL;DR: These findings indicate that suppression of AML-dependent gene activation by TLE proteins involves functional interactions with the C terminus ofAML at the nuclear matrix in situ, consistent with the concept that the Ctermini of AMl proteins support activation or repression of cell-type specific genes depending on the regulatory organization of the target promoter and subnuclear localization.

TL;DR: This review evaluates evidence that Runx2 regulates early metastatic events in breast and prostate cancers, tumor growth, and osteolytic bone disease and considers the potential for inhibition of this transcription factor as a therapeutic strategy upstream of the regulatory events contributing to the complexity of metastasis to bone.